https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53520 28.4 ng/mL) was independently associated with older age, use of beta-blockers, and number of MACE events within a 1 year period. In this patient cohort, elevated sST2 levels are associated with unplanned hospital admission due to MACE within 1 year, independent of the nature of the index cardiovascular admission.]]> Wed 28 Feb 2024 15:31:59 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32965 Wed 19 Jan 2022 15:18:41 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42651 Wed 01 Mar 2023 15:00:54 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41950 20 mm Hg and pulmonary capillary wedge pressure >15 mm Hg during right heart catheterization. LHD may lead to elevated left atrial pressure alone, which in the absence of intrinsic pulmonary vascular disease will result in PH without changes in pulmonary vascular resistance. Persistent elevation in left atrial pressure may, however, also be associated with subsequent pulmonary vascular remodeling, vasoconstriction, and an increase in pulmonary vascular resistance. Hence, there are 2 subgroups of PH due to LHD, isolated postcapillary PH and combined post- and precapillary PH, with these groups have differing clinical implications. Differentiation of pulmonary arterial hypertension and PH due to LHD is critical to guide management planning; however, this may be challenging. Older patients, patients with metabolic syndrome, and patients with imaging and clinical features consistent with left ventricular dysfunction are suggestive of LHD etiology rather than pulmonary arterial hypertension. Hemodynamic measures such as diastolic pressure gradient, transpulmonary gradient, and pulmonary vascular resistance may assist to differentiate pre- from postcapillary PH and offer prognostic insights. However, these are influenced by fluid status and heart failure treatment. Pulmonary arterial hypertension therapies have been trialed in the treatment with concerning results reflecting disease heterogeneity, variation in inclusion criteria, and mixed end point criteria. The aim of this review is to provide an updated definition, discuss possible pathophysiology, clinical aspects, and the available treatment options for PH due to LHD.]]> Tue 16 Aug 2022 14:31:43 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46897 Tue 06 Dec 2022 13:41:57 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45700 2) to provide reperfusion to patients with STEMI involve a 12-lead electrocardiogram in the ambulance, discussion between cardiologist and paramedic, followed by pre-hospital thrombolysis (PHT) delivered in ambulance to appropriate patients >60 min from the cardiac catheterisation laboratories. Patients who can access the cardiac catheterisation laboratories within 60 min are treated with primary percutaneous coronary intervention (PCI). Aims: We have previously reported excellent 12-month outcomes for patients receiving PHT and the aim of the current analysis is to look at the long term outcomes. Methods: We assessed long-term all-cause mortality and major adverse cardiovascular events of STEMI patients undergoing PHT in our health district from August 2008 to August 2013 and compared with the primary PCI group. Results: One hundred and fifty (mean age: 62 ± 13 years, males: 76%, n = 114) patients were administered PHT and 334 patients (mean age: 65 ± 13 years, males: 75%, n = 251) underwent primary PCI during the study period. During a median follow up of 6.2 years (interquartile range: 4.8–7.4 years) all-cause mortality was 16% and 19% in the PHT and primary PCI groups respectively (P = 0.4). Conclusion: Our real-world experience shows that PHT followed by early transfer to a primary PCI-capable centre is an effective reperfusion strategy, with comparable results to primary PCI, and mortality benefits are sustained to more than 6 years.]]> Thu 29 Jun 2023 13:40:43 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45386 Thu 27 Oct 2022 16:43:59 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30783 Sat 24 Mar 2018 07:37:40 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39449 Mon 25 Jul 2022 14:05:36 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46134 Fri 11 Nov 2022 15:28:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31260 P < 0.001). The 95th centile values for post-exercise PASP were calculated for the following age cohorts: <30 years; 46 mmHg, 31–50 years; 50 mmHg, 51–70 years; 52 mmHg, >70 years; 53 mmHg. There was a modest independent correlation between post-exercise PASP and (i) increasing age and (ii) resting PASP (r² = 0.35 and 0.49, respectively, P = 0.01). Conclusion: An increase of post-exercise PASP was seen in all patients undergoing SE in this study. Age was directly correlated with post-exercise PASP. Using normative data from healthy controls, treadmill SE-derived post-exercise PASP may be a useful adjunct in the diagnosis of PH.]]> Fri 03 Dec 2021 10:33:15 AEDT ]]>